Vivos Therapeutics Reports 78% Sequential Revenue Growth in Q3 2025, Shows Impact of Sleep Center of Nevada Acquisition

Vivos Therapeutics reported a 78% sequential quarter-over-quarter revenue growth in Q3 2025, driven by the first full quarter of operations since the acquisition of The Sleep Center of Nevada. The company's strategic pivot towards a direct affiliation with medical sleep practices and testing centers has shown positive results, with same-period year-over-year revenue increasing 76%. Vivos is confident in its new model and plans to expand into additional major markets.